[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.193.74. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

January 2017 - July 1959

Decade

Year

Issue

March 1, 2013, Vol 70, No. 3, Pages 247-350

In This Issue of JAMA Psychiatry

In This Issue of JAMA Psychiatry

Abstract Full Text
JAMA Psychiatry. 2013;70(3):248-248. doi:10.1001/jamapsychiatry.2013.829
Art and Images in Psychiatry

Helene Schjerfbeck's Self-portrait With Red Spot

Abstract Full Text
JAMA Psychiatry. 2013;70(3):251-252. doi:10.1001/jamapsychiatry.2013.830
Original Article

Implication of a Rare Deletion at Distal 16p11.2 in Schizophrenia

Abstract Full Text
free access
JAMA Psychiatry. 2013;70(3):253-260. doi:10.1001/2013.jamapsychiatry.71

Guha et al studied samples from 2 multiple-center discovery cohorts to determine whether a novel deletion at distal 16p11.2 is implicated in schizophrenia.

Decline in Cognitive Performance Between Ages 13 and 18 Years and the Risk for Psychosis in AdulthoodA Swedish Longitudinal Cohort Study in Males

Abstract Full Text
free access
JAMA Psychiatry. 2013;70(3):261-270. doi:10.1001/2013.jamapsychiatry.43

To assess cognitive developmental trajectories in youth and the risk for psychosis in adulthood, MacCabe et al performed a longitudinal cohort study of 4 Swedish cohorts. Verbal, spatial, and inductive ability were recorded at age 13 years and at army conscription, as well as admissions for nonaffective or affective psychoses in adulthood.

Increased Prevalence of Diverse N -Methyl-D-Aspartate Glutamate Receptor Antibodies in Patients With an Initial Diagnosis of SchizophreniaSpecific Relevance of IgG NR1a Antibodies for Distinction From N -Methyl-D-Aspartate Glutamate Receptor Encephalitis

Abstract Full Text
free access
JAMA Psychiatry. 2013;70(3):271-278. doi:10.1001/2013.jamapsychiatry.86

Steiner et al used serum samples for comparison of N-methyl-D-aspartate glutamate receptor (NMDA-R) antibodies in 121 patients with schizophrenia with those antibodies in patients with major depression or borderline personality disorder, as well as healthy controls.

Potential of Pretreatment Neural Activity in the Visual Cortex During Emotional Processing to Predict Treatment Response to Scopolamine in Major Depressive Disorder

Abstract Full Text
free access
JAMA Psychiatry. 2013;70(3):280-290. doi:10.1001/2013.jamapsychiatry.60

In a double-blind, placebo-controlled, crossover study with repeated functional magnetic resonance imaging, Furey et al determine if baseline brain activity when processing emotional information can predict treatment response to scopolamine in major depressive disorder.

Evidence for Increased Glutamatergic Cortical Facilitation in Children and Adolescents With Major Depressive Disorder

Abstract Full Text
free access
JAMA Psychiatry. 2013;70(3):291-299. doi:10.1001/2013.jamapsychiatry.24

Croarkin et al compare measures of cortical excitability and inhibition with 4 different paradigms in a group of children and adolescents with major depressive disorder (MDD) vs healthy controls.

Prevalence, Correlates, and Treatment of Lifetime Suicidal Behavior Among AdolescentsResults From the National Comorbidity Survey Replication Adolescent Supplement

Abstract Full Text
free access has expired quiz
JAMA Psychiatry. 2013;70(3):300-310. doi:10.1001/2013.jamapsychiatry.55

Using a dual-frame national sample of adolescents from the National Comorbidity Survey Replication Adolescent Supplement, Nock and coauthors estimate the lifetime prevalence of suicidal behaviors among US adolescents and the associations of retrospectively reported, temporally primary DSM-IV disorders with the subsequent onset of suicidal behaviors.

Developmental Twin Study of Attention ProblemsHigh Heritabilities Throughout Development

Abstract Full Text
free access
JAMA Psychiatry. 2013;70(3):311-318. doi:10.1001/jamapsychiatry.2013.287

Chang et al explore the relative contribution of genetic and environmental influences on symptoms of attention problems from childhood to early adulthood.

Dose-Related Psychotic Symptoms in Chronic Methamphetamine UsersEvidence From a Prospective Longitudinal Study

Abstract Full Text
free access
JAMA Psychiatry. 2013;70(3):319-324. doi:10.1001/jamapsychiatry.2013.283

In a longitudinal prospective cohort study, McKetin and coauthors determine the change in the probability of psychotic symptoms occurring during periods of methamphetamine use among 278 participants 16 years of age or older who met DSM-IV criteria for methamphetamine dependence on entry to the study but who did not meet DSM-IV criteria for lifetime schizophrenia or mania.

ANKK1, TTC12, and NCAM1 Polymorphisms and Heroin DependenceImportance of Considering Drug Exposure

Abstract Full Text
free access
JAMA Psychiatry. 2013;70(3):325-333. doi:10.1001/jamapsychiatry.2013.282

To determine the use of the Individual Burden of Illness Index for Depression (IBI-D) for assessing treatment efficacy for depressed patients, Cohen and colleagues used complete data on depressive symptom severity, functioning, and quality of life at entry and exit of level 1 of the Sequenced Treatment Alternatives to Relieve Depression study to calculate IBI-D and self-rating scale changes.

Effectiveness of a Selective, Personality-Targeted Prevention Program for Adolescent Alcohol Use and MisuseA Cluster Randomized Controlled Trial

Abstract Full Text
free access
JAMA Psychiatry. 2013;70(3):334-342. doi:10.1001/jamapsychiatry.2013.651

Conrod and coauthors report 24-month outcomes of the Adventure trial in which school staff provided interventions to students with anxiety sensitivity, hopelessness, impulsivity, and sensation seeking.

Incorporating Multidimensional Patient-Reported Outcomes of Symptom Severity, Functioning, and Quality of Life in the Individual Burden of Illness Index for Depression to Measure Treatment Impact and Recovery in MDD

Abstract Full Text
free access
JAMA Psychiatry. 2013;70(3):343-350. doi:10.1001/jamapsychiatry.2013.286

To determine the use of the Individual Burden of Illness Index for Depression (IBI-D) for assessing treatment efficacy for depressed patients, Cohen and colleagues used complete data on depressive symptom severity, functioning, and quality of life at entry and exit of level 1 of the Sequenced Treatment Alternatives to Relieve Depression study to calculate IBI-D and self-rating scale changes.

×